Yuliya Sharkovska
Overview
Explore the profile of Yuliya Sharkovska including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
368
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Demirci H, Bahena-Lopez J, Smorodchenko A, Su X, Nelson J, Yang C, et al.
bioRxiv
. 2025 Feb;
PMID: 39896580
Kidney thick ascending limb cells reabsorb sodium, potassium, calcium, and magnesium and contribute to urinary concentration. These cells are typically viewed as of a single type that recycles potassium across...
2.
Scheuer T, Brinke E, Grosser S, Wolf S, Mattei D, Sharkovska Y, et al.
Development
. 2021 Sep;
148(20).
PMID: 34557899
The inhibitory GABAergic system in the brain is involved in the etiology of various psychiatric problems, including autism spectrum disorders (ASD), attention deficit hyperactivity disorder (ADHD) and others. These disorders...
3.
Scheuer T, Sharkovska Y, Tarabykin V, Marggraf K, Brockmoller V, Buhrer C, et al.
Mol Neurobiol
. 2017 May;
55(5):3901-3915.
PMID: 28547531
Impaired postnatal brain development of preterm infants often results in neurological deficits. Besides pathologies of the forebrain, maldeveolopment of the cerebellum is increasingly recognized to contribute to psychomotor impairments of...
4.
Tsuprykov O, Ando R, Reichetzeder C, von Websky K, Antonenko V, Sharkovska Y, et al.
Kidney Int
. 2016 Apr;
89(5):1049-1061.
PMID: 27083282
Dipeptidyl peptidase (DPP)-4 inhibitors delay chronic kidney disease (CKD) progression in experimental diabetic nephropathy in a glucose-independent manner. Here we compared the effects of the DPP-4 inhibitor linagliptin versus telmisartan...
5.
Sharkovska Y, Reichetzeder C, Alter M, Tsuprykov O, Bachmann S, Secher T, et al.
J Hypertens
. 2014 Sep;
32(11):2211-23.
PMID: 25215436
Background: Despite the beneficial effects of type 4 dipeptidyl peptidase (DPP-4) inhibitors on glucose levels, its effects on diabetic nephropathy remain unclear. Method: This study examined the long-term renoprotective effects...
6.
Lauer D, Slavic S, Sommerfeld M, Thone-Reineke C, Sharkovska Y, Hallberg A, et al.
Hypertension
. 2014 Jan;
63(3):e60-7.
PMID: 24379181
Left ventricular (LV) remodeling is the main reason for the development of progressive cardiac dysfunction after myocardial infarction (MI). This study investigated whether stimulation of the angiotensin type 2 receptor...
7.
Alter M, Ott I, von Websky K, Tsuprykov O, Sharkovska Y, Krause-Relle K, et al.
Kidney Blood Press Res
. 2012 Nov;
36(1):119-30.
PMID: 23171828
Background: The need for an improved treatment for diabetic nephropathy is greatest in patients who do not adequately respond to angiotensin II receptor blockers (ARBs). This study investigated the effect...
8.
Ott I, Alter M, von Websky K, Kretschmer A, Tsuprykov O, Sharkovska Y, et al.
PLoS One
. 2012 Aug;
7(8):e42623.
PMID: 22900035
The prevalence of diabetes mellitus and its complications, such as diabetic nephropathy (DN), is rising worldwide and prevention and treatment are therefore becoming increasingly important. Therapy of DN is particularly...
9.
Hocher B, Sharkovska Y, Mark M, Klein T, Pfab T
Int J Cardiol
. 2012 Jan;
167(1):87-93.
PMID: 22217485
Background: Dipeptidylpeptidase-4 inhibition is reported to have beneficial effects on myocardial ischemia. Mechanisms might include a reduced degradation of stromal cell-derived factor-1 alpha with subsequent increased recruitment of circulating stem...
10.
Sharkovska Y, Kalk P, von Websky K, Relle K, Pfab T, Alter M, et al.
Clin Lab
. 2011 Sep;
57(7-8):507-15.
PMID: 21888014
Background: Acute kidney injury (AKI) as well as chronic renal failure are associated with a huge mortality/morbidity. However, so far no drugs have been approved for the treatment of acute...